FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 39 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR EMA Recommends Extension of Indications for Durvalumab July 27, 2020 Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event... July 20, 2022 Trastuzumab May Improve Survival in Women with Rare Endometrial Cancer August 13, 2020 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... October 7, 2021 Load more HOT NEWS Pine Trees or COVID? ESMO Announces Results of 2025 Elections 关于肺癌生物标志物检测应当了解的信息：专家问答 Υποτροπιάζων ή μεταστατικός καρκίνος κεφαλής και τραχήλου: Νέα δεδομένα αναμένεται ότι...
